Sirle Saul

Dr. Sirle Saul

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BMBelén Martinez-Gualda
Belén Martinez-Gualda
SSSirle Saul
Sirle Saul
MFMatheus Froeyen
Matheus Froeyen
DSDomique Schols
Domique Schols
PHPiet Herdewijn
Piet Herdewijn
SJSteven De Jonghe
Steven De Jonghe

26 October 2022 in Frontiers in Chemistry
Verified
Journal Article
Open access
BMBelén Martinez-Gualda
Belén Martinez-Gualda
MGMirthe Graus
Mirthe Graus
ACAnita Camps
Anita Camps
EVEmiel Vanhulle
Emiel Vanhulle
SSSirle Saul
Sirle Saul
SJSteven De Jonghe
Steven De Jonghe
RNA viral infections, including those caused by respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and Venezuelan Equine encephalitis virus (VEEV), pose a major global health challenge. Here, we report the synthesis and screening of a series of pyrrolo[2,3-b]pyridines targeting RSV, SARS-CoV-2 and/or VEEV. From this campaign, a series of lead compounds was generated that demonstrated antiviral activity in the low single-digit micromolar range against the various viruses and did not show cytotoxicity. These findings highlight the potential of 3-alkynyl-5-aryl-7-aza-indoles as a promising chemotype for the development of broad-spectrum antiviral agents.

3 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
PHPei-Tzu Huang
Pei-Tzu Huang
SSSirle Saul
Sirle Saul
SEShirit Einav
Shirit Einav
CAChristopher R. M. Asquith
Christopher R. M. Asquith
Emerging viral infections, including those caused by dengue virus (DENV) and Venezuelan Equine Encephalitis virus (VEEV), pose a significant global health challenge. Here, we report the preparation and screening of a series of 4-anilinoquinoline libraries targeting DENV and VEEV. This effort generated a series of lead compounds, each occupying a distinct chemical space, including 3-((6-bromoquinolin-4-yl)amino)phenol (12), 6-bromo-N-(5-fluoro-1H-indazol-6-yl)quinolin-4-amine (50) and 6-((6-bromoquinolin-4-yl)amino)isoindolin-1-one (52), with EC50 values of 0.63–0.69 µM for DENV infection. These compound libraries demonstrated very limited toxicity with CC50 values greater than 10 µM in almost all cases. Additionally, the lead compounds were screened for activity against VEEV and demonstrated activity in the low single-digit micromolar range, with 50 and 52 demonstrating EC50s of 2.3 µM and 3.6 µM, respectively. The promising results presented here highlight the potential to further refine this series in order to develop a clinical compound against DENV, VEEV, and potentially other emerging viral threats.

23 December 2025 in Journal of Virology
Verified
Journal Article
Open access
SSSirle Saul
Sirle Saul
BDBibha Dahal
Bibha Dahal
CLCindy Luongo
Cindy Luongo
XLXueqiao Liu
Xueqiao Liu
LYLijuan Yang
Lijuan Yang
SMShirin Munir
Shirin Munir
Human metapneumovirus (HMPV) and human parainfluenza virus 3 (HPIV3) are among the leading causes of severe pediatric respiratory illness worldwide, and there are no licensed vaccines. Here, we describe live-attenuated pediatric intranasal vaccine candidates for dual protection against HMPV and HPIV3. An attenuated chimeric bovine/HPIV3 (B/HPIV3) based on bovine PIV3, with fusion (F) and hemagglutinin-neuraminidase surface glycoproteins replaced by those of HPIV3, was designed to express HMPV subgroup A F protein, the major protective HMPV antigen. Eight viruses were generated, each containing a different version of the HMPV F ORF, including wild-type (wt), codon-optimized (BBopt or GSopt) to increase protein expression, a chimeric form (GSopt-TMCT) with the transmembrane/cytoplasmic tail (TMCT) sequence replaced with that of BPIV3 F to increase HMPV F packaging, or versions with amino acid substitutions (BBopt-D185P, GSopt-D185P, BBopt-N46V/T160F, and GSopt-N46V/T160F) to improve stability in pre-fusion form and enhance immunogenicity. In hamsters, a single intranasal dose conferred serum HMPV- and HPIV3-neutralizing antibodies and provided protection in the upper and lower respiratory tract against HMPV challenge, similar to that afforded by wt HMPV infection. Control hamsters immunized intramuscularly with two doses of HMPV pre-fusion subunit antigens stabilized by D185P or N46V/T160F mutations developed HMPV-neutralizing antibody titers, similar to those induced by the B/HPIV3/HMPV-F candidates, and were similarly protected against HMPV challenge in the lungs. However, in the upper respiratory tract, B/HPIV3/HMPV-F candidates were significantly more protective than the subunit antigens. Thus, B/HPIV3 expressing HMPV wt or pre-fusion F are promising pediatric vaccine candidates for intranasal immunization against HMPV and HPIV3. IMPORTANCE: Human metapneumovirus (HMPV) and human parainfluenza virus 3 (HPIV3) are important pediatric pathogens and need effective vaccines. We developed live-attenuated chimeric bovine/HPIV3 (B/HPIV3) expressing the fusion (F) protein of HMPV subgroup A as a bivalent pediatric intranasal vaccine against HPIV3 and HMPV. To enhance HMPV F immunogenicity, three approaches were evaluated: codon optimization to increase expression, structure-based mutations to stabilize HMPV F in pre-fusion conformation, or replacement of the HMPV F transmembrane/cytoplasmic domains with those of BPIV3 F to increase incorporation in the virus particle. In hamsters, a single intranasal dose of any of the B/HPIV3s expressing HMPV F was as immunogenic and protective against HMPV as a prior HMPV infection. In the upper respiratory tract, these provided greater protection against HMPV replication than the two intramuscular doses of the adjuvanted HMPV pre-F subunit antigens. B/HPIV3 expressing a codon-optimized pre-fusion stabilized HMPV F was advanced to a pediatric clinical study.

10 August 2025 in bioRxiv
Verified
Preprint
Open access
AIAlina Isakova
Alina Isakova
DLDaniel Dan Liu
Daniel Dan Liu
ICIvana Cvijovic
Ivana Cvijovic
RSRahul Sinha
Rahul Sinha
AEAnna E Eastman
Anna E Eastman
SQStephen R. Quake
Stephen R. Quake
Non-coding RNAs represent a widespread and diverse layer of post-transcriptional regulation across cell types and states, yet much of their diversity remains uncharted at single-cell resolution. This gap stems from the limitations of widely used single-cell RNA-sequencing protocols, which focus on polyadenylated transcripts and miss many short or non-polyadenylated RNAs. Here, we adapted single-cell RNA-sequencing on the 10x Genomics platform to capture a broad complement of coding and non-coding RNAs—including miRNAs, tRNAs, lncRNAs, histone RNAs, and non-adenylated viral transcripts. This approach enabled the discovery of rich, dynamic non-coding RNA programs across immune cells, virally infected hepatocytes, and the developing human brain. In dengue virus-infected hepatocytes, we detect non-adenylated viral transcripts and distinguish active from transcriptionally quiescent infected states, each with distinct host regulatory signatures. In brain tissue, we identify biotype-specific, cell-type– restricted non-coding RNAs, including miRNAs whose expression anticorrelates with predicted targets, consistent with post-transcriptional regulatory relationships. We show that MIR137 , one of the strongest GWAS loci associated with schizophrenia and intellectual disability, is expressed specifically in Cajal-Retzius cells, an early-born but transient population that guides subsequent cortical neuron migration. These findings demonstrate the importance of non-coding RNAs in defining cell identity and state, and show how expanded transcriptome coverage can reveal additional layers of gene control—now accessible through practical and scalable single-cell profiling.

20 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MKMarwah Karim
Marwah Karim
SSSirle Saul
Sirle Saul
LGLuca Ghita
Luca Ghita
MSMalaya Kumar Sahoo
Malaya Kumar Sahoo
CYChengjin Ye
Chengjin Ye
SEShirit Einav
Shirit Einav
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to pose serious threats to global health. We previously reported that AAK1, BIKE and GAK, members of the Numb-associated kinase family, control intracellular trafficking of multiple RNA viruses during viral entry and assembly/egress. Here, using both genetic and pharmacological approaches, we probe the functional relevance of NAKs for SARS-CoV-2 infection. siRNA-mediated depletion of AAK1, BIKE, GAK, and STK16, the fourth member of the NAK family, suppressed SARS-CoV-2 infection in human lung epithelial cells. Both known and novel small molecules with potent AAK1/BIKE, GAK or STK16 activity suppressed SARS-CoV-2 infection. Moreover, combination treatment with the approved anti-cancer drugs, sunitinib and erlotinib, with potent anti-AAK1/BIKE and GAK activity, respectively, demonstrated synergistic effect against SARS-CoV-2 infection in vitro . Time-of-addition experiments revealed that pharmacological inhibition of AAK1 and BIKE suppressed viral entry as well as late stages of the SARS-CoV-2 life cycle. Lastly, suppression of NAKs expression by siRNAs inhibited entry of both wild type and SARS-CoV-2 pseudovirus. These findings provide insight into the roles of NAKs in SARS-CoV-2 infection and establish a proof-of-principle that pharmacological inhibition of NAKs can be potentially used as a host-targeted approach to treat SARS-CoV-2 with potential implications to other coronaviruses.